Virosart® Max 0.1μm Maxicaps® MR3

Ideal for upstream and downstream applications, Maxicaps^® MR Virosart^® Max* ensures cost-effective, reliable biopharmaceutical processing. This innovative solution is tailored to meet the demands of modern bioprocessing, offering a fully contained, pre-sterilized, and pre-assembled system that significantly reduces setup time and operational risks.

Key Features

• Advanced Filtration Technology: Triple layer Polyamide membrane with 0.1 µm nominal pore size for superior filtration efficiency.
• Enhanced Membrane Protection: Increases robustness and protects the final virus retentive membranes.
• Ready-to-Use: Pre-sterilized and pre-assembled for immediate deployment.
• Risk Mitigation: Minimizes risk of contamination and operational errors.
• Space Saving: Compact design with 90% less tubing and connectors.
• Time Saving: Reduces test time by up to 4 hours.
• Cost-Effective: Lowest total cost of ownership for large-scale single-use processes.
• Flexible Connections: Compatible with Opta®, 1.5" Tri-Clamp, and other standard fittings.
• Comprehensive Testing: Each unit is integrity tested and complies with regulatory standards.
• Sterile Delivery Options: Available in both gamma-irradiated and sanitary configurations.

Versatile Formats:

Available in various sizes to accommodate different process volumes and flow rates.

For further configuration options of Maxicaps® MR Virosart® Max please contact your Sartorius sales representative.

Maxicaps® MR Virosart® Max

Available filtration area:

4.2 m² | 45.2 ft²
6.3 m² | 67.8 ft²
8.4 m² | 90.4 ft²
10.5 m² | 113 ft²
12.6 m² | 135.6 ft²
14.7 m² | 158.2 ft²
16.8 m² | 180.8 ft²
18.9 m² | 203.4 ft²

* The patented technology (DE 10 2011 105 525 B4) binds aggregates efficiently through hydrophobic interactions with polyamide, independently of process conditions such as conductivity from biological feed streams (mAbs, plasma derivates or recombinant proteins).